ArticleCurrent hepatology reports2018
The impact of direct-acting antiviral therapy for hepatitis C on hepatocellular carcinoma risk.
Article in Current hepatology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 15 citations in OpenAlex.
- A multicenter multinational retrospective study of the 1-year natural history of LI-RADS 3 observations in patients with cirrhosis.European radiology · 2026Article
- Impact of Hepatitis C Virus Infection and Treatment on Mortality in the Country of Georgia, 2015-2020.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Hepatitis C care cascade among patients with and without tuberculosis: Nationwide observational cohort study in the country of Georgia, 2015-2020.PLoS medicine · 2023Observational
- Article
- Adult form of Langerhans cell histiocytosis with pulmonary and hepatic involvement mimicking malignancy in a patient with chronic hepatitis C infection.Radiology case reports · 2021Article
- Direct-Acting Antiviral Therapy in Liver Transplant Patients With Hepatocellular Carcinoma and Hepatitis C.Transplantation direct · 2021Article
- Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database.Journal of thrombosis and haemostasis : JTH · 2021Article
- Stem Cell Therapy for Hepatocellular Carcinoma: Future Perspectives.Advances in experimental medicine and biology · 2020Review
- Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.World journal of gastroenterology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewDirect-acting antiviral agents (DAAs) eradicate hepatitis C virus (HCV) infection in the majority of patients. We critically evaluated the impact of DAAs on hepatocellular carcinoma (HCC) risk, a major complication of HCV infection. RECENT
findingsLarge cohort studies show that patients who achieve sustained virologic response (SVR) with DAAs have a significantly lower risk of developing SUMMARY: Recent studies provide evidence that DAA-induced SVR reduces HCC risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.